CTLA4 and head and neck squamous cell carcinoma: Recent clinical trials and studies suggest that immune checkpoint inhibitors, including nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4), demonstrate potential in overcoming immune evasion in HNSCC (NCT02741570) [126].